<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01225705</url>
  </required_header>
  <id_info>
    <org_study_id>UKB-2009-MED-I-JKR-01</org_study_id>
    <secondary_id>2009-015904-24</secondary_id>
    <nct_id>NCT01225705</nct_id>
  </id_info>
  <brief_title>Safety Study of Raltegravir in HIV/HCV Co-infected Patients</brief_title>
  <official_title>An Open, Prospective Study to Compare the Safety and Efficacy of Raltegravir vs. Atazanavir / Ritonavir, Both in Combination With Tenofovir DF and Emtricitabine, in the Treatment of HIV-infection in ART Naive Subjects With HCV Co-infection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr. Axel Baumgarten, Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Christoph Stephan, Frankfurt/M</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Stefan Esser, Essen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Keikawus Arastéh, Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prof. Dr. Hans-Jürgen Stellbrink, Hamburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Thomas Lutz, Frankfurt/M</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Jörg Gölz , Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current European AIDS Clinical Society (EACS) guidelines for the treatment of HIV infection&#xD;
      recommend a combination antiretroviral regimen composed of two nucleoside reverse&#xD;
      transcriptase inhibitors plus a ritonavir boosted protease inhibitor or a non-nucleoside&#xD;
      reverse transcriptase inhibitor.&#xD;
&#xD;
      The non-nucleoside reverse transcriptase inhibitors licensed for naïve patients - nevirapine&#xD;
      and efavirenz - have both been asociated with increased rates of hepatotoxicity (nevirapine)&#xD;
      and CNS toxicity (efavirenz) in HIV/HCV co-infected patients. Although PI-based therapy has&#xD;
      dramatically reduced morbidity and mortality, it has been limited by complex dosing regimens&#xD;
      and toxicities, leading to adherence challenges. Varying degree of liver insufficiency may&#xD;
      necessitate pharmacokinetic monitoring of the protease inhibitor and may necessitate dose&#xD;
      adjustments. In HIV/HCV co-infected patients HAART based on another class of antiretrovirals&#xD;
      than NNRTI or PI may thus offer advantages with regard to adverse events and thus long-term&#xD;
      efficacy.&#xD;
&#xD;
      The overall intention of this trial is to examine in a non-inferiority design the safety and&#xD;
      efficacy of a raltegravir based HAART with a standard-of-care HAART in HIV-/HCV co-infected&#xD;
      patients. The standard of care used in this study will be atazanavir/ritonavir. All patients&#xD;
      will in addition receive a fixed combination of tenofovir and emtricitabine.&#xD;
&#xD;
      The primary end-point is the rate of hepatotoxic events, defined by ALT elevations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    no pts recruited&#xD;
  </why_stopped>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary objective</measure>
    <description>there is no difference in the rate of grade 1/2, or 3/4 ALT elevations&#xD;
there is a higher incidence of grade 1 - 4 hyperbilirubinemias in the ATV/r arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary objectives</measure>
    <description>Other parameters of safety and efficacy will be compared between both arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>HIV</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Raltegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>45 patients will receive open label raltegravir, in addition to the common backbone tenofovir and emtricitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atazanavir/ritonavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>45 patients will receive open label atazanavir/ritonavir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltegravir</intervention_name>
    <description>Patients will be randomized 1:1 to either the experimental or the active control arm</description>
    <arm_group_label>Raltegravir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir/ritonavir</intervention_name>
    <description>Patients will be randomized 1:1 to either the experimental or the active control arm</description>
    <arm_group_label>Atazanavir/ritonavir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV and Hepatitis C co-infected patients&#xD;
&#xD;
          -  indication for HAART according to current German-Austrian guidelines&#xD;
&#xD;
          -  HAART naive&#xD;
&#xD;
          -  no primary NRTI / Integrase / PI associated resistance mutation according to the&#xD;
             Stanford algorithm at screening; every patient MUST have a genotypic resistance assay&#xD;
             prior baseline available (&lt; 6 months prior to baseline)&#xD;
&#xD;
          -  women of childbearing age: negative pregnancy test&#xD;
&#xD;
          -  ability to sign written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  advanced liver cirrhosis Child-Pugh B or C or decompensated liver disease&#xD;
&#xD;
          -  Pegylated interferon / ribavirin or other anti-HCV therapy; planned anti-HCV therapy&#xD;
             for duration of the study (48 weeks).&#xD;
&#xD;
          -  acute or chronic hepatitis B infection&#xD;
&#xD;
          -  acute hepatitis A or other hepatotropic virus infections&#xD;
&#xD;
          -  any other chronic liver disease such as alcohol abuse or hemosiderosis&#xD;
&#xD;
          -  use or planned use (for the duration of the study, 48 weeks) of rifampicin, St. John´s&#xD;
             wort and drugs that are metabolized via the cytochrome P450 system with a narrow&#xD;
             therapeutic PK-range such as astemizole, terfenadine, cisapride, pimozide, chinidin,&#xD;
             bepridil, triazolam, midazolam, ergotamine, dihydroergotamin, ergometrine,&#xD;
             methyl-ergometrine. FOR OTHER COMEDICATIONS please consult with the SPC of Raltegravir&#xD;
             (Isentress®), Atazanavir (Reyataz®), Ritonavir (Norvir®), your hospital pharmacist,&#xD;
             www.hiv-drug-interactions.org or the principal investigator in case of uncertainty.&#xD;
&#xD;
          -  new AIDS defining event, except for Kaposi sarcoma, &lt; 1 months prior to screening&#xD;
&#xD;
          -  malignancy, except for Kaposi sarcoma, with current radio- or chemotherapy&#xD;
&#xD;
          -  history of organ transplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Auguste Viktoria Hospital (AVK)</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxiszentrum Kaiserdamm</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice Dupke, Carganico, Baumgarten</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine I, Bonn University</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infektiologikum Frankfurt</name>
      <address>
        <city>Frankfurt / Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Frankfurt</name>
      <address>
        <city>Frankfurt / Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infektionsmedizinisches Centrum Hamburg (ICH)</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <study_first_submitted>October 20, 2010</study_first_submitted>
  <study_first_submitted_qc>October 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2010</study_first_posted>
  <last_update_submitted>June 2, 2015</last_update_submitted>
  <last_update_submitted_qc>June 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <responsible_party>
    <name_title>Rheinische Friedrich-Wilhelms-Universität Bonn, Germany</name_title>
    <organization>Bonn University</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

